Lexaria Bioscience continues to innovate in drug delivery technology, with a primary focus on its proprietary DehydraTECH™ platform for enhancing the bioavailability of bioactive compounds, including cannabinoids and, more recently, GLP-1 agonists.
The company is scheduled to report its fiscal Q2 2026 earnings around April 13–14, 2026 (before market open). Wall Street analysts currently expect an EPS of approximately -$0.10 and revenue in the range of $50,000–$100,000.
In the previous quarter (fiscal Q1 2026, ended November 30, 2025), Lexaria reported an EPS of -$0.07, beating the consensus estimate (which ranged from -$0.08 to -$0.13 depending on the source) by a meaningful margin.
Despite occasional beats on estimates, Lexaria continues to face significant financial headwinds typical of a development-stage biotech company. It carries a highly negative return on equity (recent TTM figures around -155%) and deeply negative net and operating margins.
For the most recently reported quarter, Lexaria recorded a net loss attributable to shareholders of approximately $1.6 million. Operating expenses drove an operating loss of a similar magnitude, with negative gross profit in periods of low or zero revenue. EBITDA was also negative by roughly $1.57 million, reflecting ongoing R&D investment (particularly in GLP-1 studies) and general corporate costs.
